论文部分内容阅读
目的观察乳腺癌组织中血管内皮生长因子C(VEGF-C)和血管内皮生长因子受体3(VEGFR-3)的表达及其临床意义。方法采用免疫组化法检测76例乳腺癌组织、62例癌旁乳腺组织中VEGF-C及VEGFR-3的表达情况,并比较在不同组织中的表达。分析不同临床因素的乳腺癌患者VEGF-C及VEGFR-3的表达情况。结果乳腺癌组织标本中有57例出现VEGF-C阳性表达(75.0%,57/76),而癌旁组织中5例VEGF-C阳性(8.1%,5/62),二者比较差异有统计学意义(P<0.05)。46例淋巴结转移的标本中有41例VEGF-C阳性(89.1%,41/46),30例淋巴结未转移标本中16例VEGF-C阳性(53.3%),二者比较差异有统计学意义(P<0.05)。乳腺癌组织VEGF-C阳性表达情况与年龄、肿瘤直径、临床分期均无关(P均>0.05)。乳腺癌组织标本中有52例出现VEGFR-3阳性(68.4%,52/76),而癌旁组织中4例VEGFR-3阳性(6.5%,4/62),二者比较差异有统计学意义(P<0.05)。46例淋巴结转移的标本中有38例VEGFR-3阳性(82.6%,38/46),而30例淋巴结未转移标本中仅13例VEGFR-3阳性(43.3%,13/30),二者比较差异有统计学意义(P<0.05)。乳腺癌组织VEGFR-3阳性表达情况与年龄、肿瘤直径、临床分期均无关(P均>0.05)。乳腺癌组织中VEGF-C与VEGFR-3呈正相关(r=0.758,P<0.05)。结论乳腺癌组织VEGF-C和VEGFR-3的表达明显增强,并与淋巴结转移密切相关,通过对VEGF-C及VEGFR-3的联合检测可能更有利于准确评估预后,且该信号系统可能成为抗某些肿瘤淋巴道转移的特异性靶标。
Objective To observe the expression of vascular endothelial growth factor C (VEGF-C) and vascular endothelial growth factor receptor 3 (VEGFR-3) in breast cancer and its clinical significance. Methods Immunohistochemistry was used to detect the expression of VEGF-C and VEGFR-3 in 76 cases of breast cancer tissues and 62 cases of paracancer tissues. The expressions of VEGF-C and VEGFR-3 in different tissues were compared. To analyze the expression of VEGF-C and VEGFR-3 in breast cancer patients with different clinical factors. Results The positive expression of VEGF-C was found in 57 cases of breast cancer (75.0%, 57/76), while the positive expression of VEGF-C in 5 cases (8.1%, 5/62) was statistically significant Significance (P <0.05). Of the 46 cases with lymph node metastasis, 41 were positive for VEGF-C (89.1%, 41/46) and 16 were positive for VEGF-C (53.3%) in 30 cases of lymph node metastasis, with significant difference between the two P <0.05). The positive expression of VEGF-C in breast cancer tissue was not related to age, tumor diameter and clinical stage (all P> 0.05). In breast cancer specimens, VEGFR-3 was positive in 52 cases (68.4%, 52/76), while in adjacent tissues 4 cases were VEGFR-3 positive (6.5%, 4/62), the difference was statistically significant (P <0.05). Of the 46 lymph node metastases, 38 were VEGFR-3 positive (82.6%, 38/46), whereas only 13 of the 30 lymph node metastases were positive for VEGFR-3 (43.3%, 13/30) The difference was statistically significant (P <0.05). The positive expression of VEGFR-3 in breast cancer tissue was not related to age, tumor diameter and clinical stage (all P> 0.05). VEGF-C and VEGFR-3 in breast cancer tissues were positively correlated (r = 0.758, P <0.05). Conclusions The expression of VEGF-C and VEGFR-3 in breast cancer tissues is significantly increased and closely related to lymph node metastasis. Combined detection of VEGF-C and VEGFR-3 may be more helpful for the accurate assessment of prognosis, and the signaling system may become a Specific Targets for Certain Lymphatic Metastases in Tumors.